ong-term high-flow nasal cannula therapy in patients with stable COPD: a prospective, randomized crossover study - High-flow nasal cannula therapy for stable COPD

Kobe City Medical Center General Hospital Department of Respiratory Medicine0 个研究点目标入组 30 人开始时间: 2015年5月21日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients with severe kidney, liver or cardiovascular disease. 2. Patients with active malignant tumor. 3. Patients with acute disease. 4. Patients with any history of obstructive sleep apnea syndrome. 5. Patients with diseases affecting the efficacy endpoints who are regarded as inadequate for the study by the investigators. 6. Patients who have experienced a COPD exacerbation within the past 6 weeks prior to the informed consent. 7. Patients who have received nocturnal noninvasive positive pressure ventilation (NPPV), or had received it within 6 weeks prior to the informed consent. 8. Patients with history of tracheotomy, severe pharyngeal surgery or severe nasal cavity surgery within the last 6 months. 9. Patients who are pregnant. 10. Patients with cognitive impairment or mental disorder who are regarded as inadequate to evaluate for the study by the investigators. 11. Patients who are regarded as being unable to operate the myAIRVO2 inadequately at home by the investigators. 12. Patients who have participated in the other study at the time of the informed consent, or will participate in the other study. 13. Any other cases who are regarded as inadequate for the study enrollment by the investigators.

发起方

Kobe City Medical Center General Hospital Department of Respiratory Medicine